3/13
05:23 am
tnxp
Tonix Pharmaceuticals GAAP EPS of -$3.98 misses by $0.82, revenue of $5.39M beats by $2.42M [Seeking Alpha]
Low
Report
Tonix Pharmaceuticals GAAP EPS of -$3.98 misses by $0.82, revenue of $5.39M beats by $2.42M [Seeking Alpha]
3/12
06:03 pm
tnxp
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights [Yahoo! Finance]
3/12
05:30 pm
tnxp
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Low
Report
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
3/10
08:00 am
tnxp
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia
Low
Report
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia
3/9
05:07 pm
tnxp
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting [Yahoo! Finance]
3/9
04:30 pm
tnxp
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
Low
Report
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
3/5
04:57 pm
tnxp
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development [Yahoo! Finance]
3/5
04:15 pm
tnxp
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
Low
Report
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development
3/3
05:00 pm
tnxp
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting [Yahoo! Finance]
3/3
04:30 pm
tnxp
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
Low
Report
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
3/3
06:37 am
tnxp
Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market [Yahoo! Finance]
3/3
06:00 am
tnxp
Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market
Low
Report
Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market
2/25
07:18 am
tnxp
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March [Yahoo! Finance]
2/25
07:00 am
tnxp
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
Medium
Report
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
1/30
07:00 am
tnxp
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
Medium
Report
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
1/17
01:11 am
tnxp
Tonix Pharmaceuticals (NASDAQ:TNXP) was upgraded by analysts at
Wall Str
Low
Report
Tonix Pharmaceuticals (NASDAQ:TNXP) was upgraded by analysts at
Wall Str
1/6
07:00 am
tnxp
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
Low
Report
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
1/3
01:08 am
tnxp
Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by analysts at
Wall S
Medium
Report
Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by analysts at
Wall S
12/30
08:12 am
tnxp
Tonix prices 615,025 shares at $16.26 in registered direct offering [Yahoo! Finance]
Medium
Report
Tonix prices 615,025 shares at $16.26 in registered direct offering [Yahoo! Finance]
12/29
08:12 am
tnxp
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering [Yahoo! Finance]
12/29
08:01 am
tnxp
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) [Yahoo! Finance]
12/29
07:57 am
tnxp
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
Medium
Report
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
12/29
07:45 am
tnxp
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Medium
Report
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
12/16
07:51 am
tnxp
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University [Yahoo! Finance]
12/16
07:00 am
tnxp
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
Low
Report
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University